-+ 0.00%
-+ 0.00%
-+ 0.00%

SNB Capital Cuts Avalon Pharma's PT, Confirms Neutral Rating

MT Newswires·11/05/2026 08:40:00
Listen to the news
08:40 AM EST, 11/05/2026 (MT Newswires) -- SNB Capital on Wednesday lowered the price target for pharmaceutical company Middle East Pharmaceutical Industries Co. (SASE:4016), d/b/a Avalon Pharma, to 83.70 Saudi riyals from 146.40 riyals and reiterated its neutral rating. (MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www.mtnewswires.com/contact-us)